Log in

NASDAQ:PLXPPLx Pharma Stock Price, Forecast & News

-0.23 (-5.88 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $3.68
50-Day Range
MA: $2.76
52-Week Range
Now: $3.68
Volume44,503 shs
Average Volume24,070 shs
Market Capitalization$33.71 million
P/E RatioN/A
Dividend YieldN/A
PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral non-steroidal anti-inflammatory drugs using the PLxGuard delivery system, such as PL1200 Ibuprofen 200 mg, a GI-safer ibuprofen product for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. The company was founded in 2002 and is headquartered in Houston, Texas.
Read More
PLx Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PLXP



Sales & Book Value

Annual Sales$570,000.00
Book Value($1.16) per share


Net Income$-20,500,000.00
Net Margins-3,369.72%


Market Cap$33.71 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter.

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

How has PLx Pharma's stock been impacted by COVID-19 (Coronavirus)?

PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PLXP shares have decreased by 23.5% and is now trading at $3.68. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PLx Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PLx Pharma.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for PLx Pharma.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc (NASDAQ:PLXP) issued its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.37) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.03. View PLx Pharma's earnings history.

Has PLx Pharma been receiving favorable news coverage?

News coverage about PLXP stock has trended somewhat negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PLx Pharma earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPLx Pharma.

Who are some of PLx Pharma's key competitors?

What other stocks do shareholders of PLx Pharma own?

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the following people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 65)
  • Ms. Natasha Giordano, CEO, Pres & Director (Age 59)
  • Mr. Gary L. Mossman, Sr. Advisor (Age 78)
  • Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 66)
  • Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 51)

When did PLx Pharma IPO?

(PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Heritage Way Advisors LLC (0.46%). Company insiders that own PLx Pharma stock include Michael J Valentino and Park West Asset Management Llc. View institutional ownership trends for PLx Pharma.

Which institutional investors are buying PLx Pharma stock?

PLXP stock was bought by a variety of institutional investors in the last quarter, including Heritage Way Advisors LLC. Company insiders that have bought PLx Pharma stock in the last two years include Michael J Valentino, and Park West Asset Management Llc. View insider buying and selling activity for PLx Pharma.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $3.68.

How big of a company is PLx Pharma?

PLx Pharma has a market capitalization of $33.71 million and generates $570,000.00 in revenue each year. The biotechnology company earns $-20,500,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis. PLx Pharma employs 12 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is www.plxpharma.com.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 973-409-6541 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.